Respiratory

Three scientists discuss the global race for a COVID-19 vaccine.

A panel has given a “weak recommendation” for the use of remdesivir in patients with severe coronavirus disease 2019.

Approval was based on trials that reported significantly reduced exacerbation rates compared with dual-combination therapies.

Some patients affected by COVID-19 may be concerned about hyposmia (reduced ability to smell) or anosmia (loss of smell) that they experience after contracting the virus.

Pfizer and BioNTech SE announced that 2 of its most successful vaccine candidates received Fast Track designation from the FDA, opening the avenue for speedy development.

“Pharmacists should ensure that patients have a written asthma action plan.”

The therapy will also be available for individuals with asthma and suspected COVID-19 infection.

Moderna announced interim analysis results of its investigational COVID-19 vaccine candidate, mRNA-1273, from an ongoing phase 1 study.

The FDA has granted emergency use authorization to an additional combination diagnostic test for influenza and COVID-19.

In a new guidance, the FDA provides recommendations for those developing COVID-19 vaccines to ensure safety and efficacy.

Julie Ann Justo, infectious diseases clinical pharmacist and associate professor at the University of South Carolina College of Pharmacy, discusses the latest data from Gilead's trials for Remdesivir, a potential COVID-19 treatment.

Results of a PLOS ONE study determined a positive relationship between COPD and smoking and mortality rates from COVID-19.

The FDA warned that the dosing cups, which were missing some graduation markings, could cause an accidental overdose.

The CDC released an updated vaccination guidance on administering routine vaccinations amid the coronavirus disease 2019 (COVID-19) pandemic.

Since the emergency use authorization was granted, new data on heart risks associated with hydroxychloroquine and chloroquine have been revealed.

Pharmacies are preparing for what is expected to be a surge in flu vaccinations this year as Americans are putting a greater focus on staying healthy amid the coronavirus pandemic.

Officials with the FDA have approved imipenem, cilastatin, and relebactam (Recarbrio, Merck) for the treatment of adults with hospital-acquired and ventilator-associated bacterial pneumonia. 

A close look at their potential to interact with other medications is required to limit the risk of adverse outcomes for patients.

Investigators are evaluating a variety of medications for the novel coronavirus disease 2019 (COVID- 19), and the possible treatment landscape is rapidly evolving.

Hydroxychloroquine has been widely used for treatment of COVID-19, despite the lack of strong evidence supporting its efficacy.

New clinical trial updates on remdesivir as a potential treatment for coronavirus disease 2019 (COVID-19) were announced today.

Regeneron and Sanofi will amend their ongoing trial of sarilumab (Kevzara) to enroll only “critical” hospitalized patients with COVID-19.

The guidelines provide clinical recommendations to providers treating patients with coronavirus disease 2019 (COVID-19).

In 2 prior clinical studies, gimsilumab demonstrated favorable results in treating the novel coronavirus.

In collaboration with Spectrum Solutions and Accurate Diagnostic Labs, RUCDR Infinite Biologics developed the new collection approach, which utilizes saliva as the primary test biomaterial for COVID-19.